

## Outcome of neonates born to mothers with premature rupture of membranes

Dr. Sanjeev Kumar

Assistant professor, Dept. pediatrics, Anugrah Narayan Magadh medical college and hospital Gaya, Bihar, India

### Abstract

The aim of the study is to evaluate an active conservative management (tocolysis and antibiotics administration) in preterm premature rupture of the membranes (PROM), applied to 215 singleton pregnancies. Pregnancies are continued until 37 weeks of gestation if the clinical and biological follow-up shows no risk for the mother and the fetus. The neonatal results were analysed by statistical methods and were compared to the outcome of a control group of premature neonates.

Our results show that the outcome is mostly determined by gestational age at membrane rupture. No benefit nor risk was added when glucocorticoids were administered. Clinical suspicion of chorioamnionitis increases the risk of neonatal infection. A prolonged latency period (> 7 days) does not increase the maternal or fetal infection risk. When birth happened before 35 weeks and before 37 weeks, the premature neonate after PROM has a lower incidence of hyaline membrane disease and neonatal death compared with the control group. These results are in favor of an active conservative management in PROM.

**Keywords:** Chorioamnionitis, glucocorticoid, hyaline membrane disease, latency period, neonatal death, neonatal infection, premature rupture of fetal membranes

### 1. Introduction

Premature rupture of the fetal membranes (PROM) leads to two main perinatal problems: prematurity and infection [3]. Prematurity occurs because usually labor begins shortly after the rupture [8]. Infection is the consequence of an open amniotic fluid cavity allowing germs to contaminate both the mother and the fetus]. In the literature, there is a lack of consensus about the attitude to adopt towards premature rupture of membranes [7]. The obstetrician is confronted with the choice of an optimal follow up either with or without tocolysis, antibiotic prevention and hyaline membrane disease prevention by glucocorticoids [3,4], depending on the risk for the neonate and the mother.

Corticoids are known to be related to an increased risk of infection, and in a situation such as PROM where infection is threatening it may be dangerous to use them. For some authors glucocorticoid administration increases the maternal infection risk but not the neonatal infection risk [1], while for other authors it increases the neonatal but not the maternal infection risk.

Other authors find that glucocorticoid administration does not increase any infection risk and finally, there are authors who find an increased maternal and neonatal infection risk [3]. We do not find any increased incidence of chorioamnionitis nor neonatal infection when patients received  $\beta$ -methasone. Since we observe no benefit in glucocorticoids administration and there is doubt about the infection risk, we recommend to not use them.

When chorioamnionitis is clinically suspected, pregnancy should be stopped. The increased risk of neonatal infection associated with chorioamnionitis seems generally accepted [2,3] but the relation with neonatal death is still controversial [16]. Our results show that clinical suspicion of chorioamnionitis is related with a higher incidence of neonatal infection but not with higher neonatal death rate.

In our study we have no prenatal death, no congenital malformation, but fetuses seem to be slower in their growth. Our control group compares the premature neonate after

PROM with a control premature neonate. The results show less HMD and a lower rate of neonatal death after PROM. The principle that PROM decreases the risk of HMD [3,9] and the results of BLACKMON [3] who finds a decreased perinatal mortality are in agreement with our results.

### 2. Methodology

Two hundred and fifteen women between 24 and 36 weeks of pregnancy with premature rupture of the membranes (PROM) were admitted in this study.

Diagnosis of PROM was based on patient's story, sterile speculum examination showing pooling amniotic fluid, and microscopic examination for "ferning". At admission, a cervical culture for group  $\beta$  streptococcus was performed.

Criteria of exclusion were: major fetal congenital anomalies, fetal death, fetal distress, multiple pregnancies, women in labor and any obstetrical reason for immediate delivery such as vaginal bleeding or evidence of chorioamnionitis. Treatment consisted in bed rest at the hospital, antibiotics continuously given (ampicillin 3  $\chi$  1 g IVD or erythromycin 4  $\chi$  500 mg in case of allergy), and intravenous tocolysis by ritodrine if labor began. No vaginal disinfection was performed. Glucocorticoids (-methasone 12 mg/day IM for two days repeated once a week) were given only before 32 weeks and by the discretion of the attendant physician.

Follow-up of the patients consisted of measuring the maternal temperature, evaluating uterine tenderness, and performing fetal heart rate monitoring twice a day. Maternal leucocytosis and blood sedimentation speed was measured every two days. Once a week an ultrasound examination was performed to check fetal well-being. A cervical/vaginal culture was also done once a week to certify a local sterilization. In case of resistance to ampicillin, the antibiotic treatment was adapted. Pregnancy was terminated in case of suspected chorioamnionitis (based on any of the following signs: maternal fever greater than 38 °C; leucocytosis superior to 15000; uterine tenderness; foul smelling amniotic fluid

discharge), fetal distress, labor despite tocolysis, and when gestational age reached 37 weeks. Antibiotics were given during seven days after birth to all patients. The latency period is the time between membrane rupture and birth. A latency period of less than two days is considered a failure of conservative management.

Results were evaluated by the neonatal outcome: prematurity, birth weight, Apgar score at 1 and 5 min, incidence of neonatal hyaline membrane disease (HMD), neonatal infection, and early neonatal death (first week of life). Diagnosis of hyaline membrane disease was based on clinical evaluation and on characteristic lung radiography; wet lung, transient respiratory distress, and post-anoxic distress were diagnosed separate from HMD.

Neonatal infection consisted of a positive central culture such as blood, cephalo-rachidian fluid or urine, or a clinical evaluation showing evidence of infection (leukocytosis, response to antibiotics.). Neonatal outcome was compared to neonatal outcome of babies born prematurely for another etiological reason; each premature neonate following PROM was matched with a premature neonate of the same birth age and year of birth in order to compare similar neonatal management. The benefit of pregnancy prolongation after PROM and the group of neonates born at 37 weeks of gestation (not premature) were not considered when compared to the control group.

Statistical analysis consisted of Chi-square tests of independence performed on groups separated by the procedure CROSSTAB of the statistical package SPSS.

**3. Results**

215 women with single pregnancies and PROM entered this retrospective study. Gestational age ranged from 26 weeks to 36 weeks of amenorrhea, 113 PROM cases occurred before 35 weeks. Reasons for termination of pregnancy and the overall neonatal results are listed (table I). In our series we had no

congenital malformation and no prenatal death. Pregnancy age at membrane rupture is a major factor in determining the outcome (table II). The latency period decreases with advanced gestational age. Suspicion of chorioamnionitis is significantly more frequent at low gestational age.

Glucocorticoid treatment in PROM occurring before 33 weeks of pregnancy was administered in 28 cases out of 58 (48.3%). No difference in neonatal outcome are found respectively with and without treatment: rates of hyaline membrane disease (17.9% vs 20.0%), of neonatal infection (21.4% vs 26.7%) and of neonatal death (10.7% vs 3.3%) are similar. The rate of suspected chorioamnionitis is also similar in the two groups (35.7% vs 36.7%).

When pregnancy is terminated because of the suspicion of chorioamnionitis, the neonatal outcome is compromised; the incidence of neonatal infection is significantly ( $P < 0.001$ ) related to the suspicion of chorioamnionitis (table III). Seventy cases (32.6%) of PROM had a prolonged latency period ( $> 7$  days). When comparing the pregnancy outcome with PROM having a shorter latency period, we found no difference. Especially, the incidence of chorioamnionitis (14.5% vs 24.3%, respectively in the short and prolonged latency groups) and of neonatal infection (6.9% vs 12.9%) are not statistically different.

When pregnancy termination was motivated by a gestational age of 37 weeks, ( $N = 46, 21.4%$ ) fetal growth seems to be slowed down. Indeed, the incidence of birth weight inferior to the tenth percentile was significantly ( $P < 0.001$ ) more frequent in the group reaching 37 weeks of gestation ( $N = 9, 19.6%$ ; versus  $N = 4, 2.4%$  in the group not reaching 37 weeks). When PROM led to premature birth, the premature neonates before 33 weeks of gestation did not differ from the control premature neonates (table IV). When birth happened before 35 weeks and before 37 weeks, there is a lower incidence of HMD and neonatal death in premature neonates following PROM compared to the control group.

**Table 1:** Premature rupture of the membranes: Conservative management, overall results

<b>Table I. Premature rupture of the membranes: Conservative management, overall results</b>				
	<b>PROM</b>		<b>PROM</b>	
	<b>before 35 weeks</b>		<b>before 37 weeks</b>	
	<b>113 cases</b>		<b>215 cases</b>	
<b>Termination of pregnancy:</b>				
- suspicion of chorioamnionitis	31	27.4%	38	17.7%
- 37 weeks reached	7	6.2%	46	21.4%
- failure of tocolysis	62	54.9%	113	52.6%
- pathologic fetal heart rate	10	8.8%	13	6.0%
- others	3	2.7%	5	2.3%
<b>Neonatal results:</b>				
- prematurity:				
* before 37 weeks	106	93.8%	169	78.6%
* before 35 weeks	85	75.2%	85	39.5%
* before 33 weeks	51	45.1%	51	23.7%
- birth weight:				
* <1000 g	8	7.1%	8	3.7%
* <1500 g	26	23.0%	26	12.1%
* <2000 g	58	51.3%	60	27.9%
* <2500 g	85	75.2%	111	51.6%
- Apgar scores <7:				
* at 1 min	71	62.8%	99	46.0%
* at 5 min	31	27.4%	34	15.8%
- Hyaline membrane disease	15	13.3%	15	7.0%
- Neonatal infection	18	15.9%	19	8.8%
- Neonatal death	4	2.5%	4	1.9%

**4. Discussion**

The first problem relating to PROM seems to be infection, maternal and/or neonatal. The studies of JOHNSON [18] and BLACKMON [3] show that the later the PROM occurs during the pregnancy, the smaller is the overall risk of infection. This is in agreement with our results. However, according to others, pregnancy age modifies the risk of chorioamnionitis but not the neonatal sepsis [1].

The controversy about the benefit versus the risk of delaying labor after PROM is the main problem concerning the management of PROM. According to the literature, the risk of chorioamnionitis is variously related to the latency period:

many authors find no relationship [6, 14, 18] while others find a negative relationship [1, 9]. Similar controversial results are found about the incidence of neonatal infection, but the actual conclusion seems to be that there is no relationship between the length of the latency period and the neonatal infection.

We find that a prolonged latency period (> 7 days) does not increase the risk of chorioamnionitis nor the risk of neonatal infection. The benefit of conservative management lies in the reduction of HMD, a major complication of prematurity. A recent report [3] shows the positive effect of a prolonged latency even if previous studies tend to find no relationship [1, 9].

**Table 2**

	Date of PROM								CHI <sup>2</sup>
	before 28 weeks		28-32 weeks		33-34 weeks		35-36 weeks		
	N = 24	11.2%	N = 42	19.5%	N = 47	21.9%	N = 102	47.4%	
<b>Latency period:</b>									
- <2 days	0	0.0%	5	11.9%	11	23.4%	28	27.5%	P<0.001
- 2 to 7 days	10	41.7%	17	40.5%	20	42.6%	60	58.8%	
- >7 days	14	58.3%	20	47.6%	16	34.0%	14	13.7%	
<b>Termination of pregnancy:</b>									
- suspicion of chorioamnionitis	7	29.2%	18	42.9%	6	12.8%	7	6.9%	P<0.001
- 37 weeks reached	2	8.3%	0	0.0%	5	10.6%	39	38.2%	P<0.001
- failure of tocolysis	12	50.0%	20	47.6%	30	63.8%	51	50.0%	n.s.
- pathologic fetal heart rate	3	12.5%	4	9.5%	3	6.4%	3	2.9%	n.s.
- others	0	0.0%	0	0.0%	3	6.4%	2	2.0%	-
<b>Neonatal results:</b>									
- prematurity:									
* before 37 weeks	22	91.7%	42	100.0%	42	89.4%	63	61.8%	P<0.001
* before 35 weeks	20	83.3%	41	97.6%	24	51.1%	-	-	-
* before 33 weeks	20	83.3%	31	73.8%	-	-	-	-	-
- birth weight:									
* <1000 g	8	33.3%	0	0.0%	0	0.0%	0	0.0%	P<0.001
* <1500 g	16	66.7%	9	21.4%	1	2.1%	0	0.0%	P<0.001
* <2000 g	18	75.0%	34	81.0%	6	12.8%	2	2.0%	P<0.001
* <2500 g	20	83.3%	39	92.9%	26	55.3%	26	25.5%	P<0.001
- Apgar scores <7:									
* at 1 min	19	79.2%	32	76.2%	20	42.6%	28	27.5%	P<0.001
* at 5 min	12	50.0%	16	38.1%	3	6.4%	3	2.9%	P<0.001
- Hyaline membrane disease	7	29.2%	7	16.7%	1	2.1%	0	0.0%	P<0.001
- Neonatal infection	6	25.0%	10	23.8%	2	4.3%	1	1.0%	P<0.001
- Neonatal death	3	12.5%	1	2.4%	0	0.0%	0	0.0%	P<0.001

**Table 3: Effects of chorioamnionitis on neonatal outcome**

	Chorioamnionitis		No chorioamnionitis		CHI <sup>2</sup>
	N = 38	7.7%	N = 177	82.3%	
<b>Prematurity:</b>					
* before 37 weeks	38	100.0%	131	74.0%	P<0.001
* before 35 weeks	27	71.1%	58	32.8%	P<0.001
* before 33 weeks	17	44.7%	34	19.2%	P<0.001
<b>Birth weight:</b>					
* <1000 g	4	10.5%	4	2.3%	P<0.05
* <1500 g	9	23.7%	17	9.6%	P<0.05
* <2000 g	21	55.3%	39	22.0%	P<0.001
* <2500 g	27	71.1%	84	47.5%	P<0.01
<b>Apgar scores &lt;7:</b>					
* at 1 min	26	68.4%	73	41.2%	P<0.01
* at 5 min	13	34.2%	21	11.9%	P<0.001
Hyaline membrane disease	3	7.9%	12	6.8%	n.s.
Neonatal infection	9	23.7%	10	5.6%	P<0.001
Neonatal death	0	0.0%	4	2.2%	n.s.

Our results however, also show a trend of decreasing incidence of HMD with prolonged latency, but it is not statistically significant ( $P = 0.079$  for PROM before 35 weeks). In order to accelerate lung maturation, the administration of  $\beta$ -methasone is recommended. The majority of reported studies find no

difference in the incidence of HMD when corticosteroids were given. Our results are in agreement with these studies. But, according to SPINNATO these results are not to be considered because the treatment is applied to a low risk population and needs, for further evaluation, to be applied where the potential benefit of lung maturation really exists.

**Table IV.** Comparison of neonatal outcome of premature neonates after PROM with control premature neonates

	Date of birth														
	before 33 weeks; N = 100			before 35 weeks; N = 165			before 37 weeks; N = 320								
	after PROM	others	Chi <sup>2</sup>	after PROM	others	Chi <sup>2</sup>	after PROM	others	Chi <sup>2</sup>						
	N=51	51.0%		N=85	51.5%		N=169	52.3%		N=154	47.7%				
<b>Birth weight:</b>															
• <1000 g	8	15.7%	11	22.4%	n.s.	8	9.4%	11	12.7%	n.s.	8	4.7%	11	7.1%	n.s.
• <1500 g	25	49.7%	33	67.3%	n.s.	26	30.4%	36	45.0%	n.s.	26	15.4%	41	26.6%	$P<0.05$
• <2000 g	48	94.1%	45	91.8%	n.s.	57	67.1%	58	72.5%	n.s.	60	35.5%	73	46.8%	$P<0.05$
• <2500 g	50	98.0%	49	100.0%	n.s.	72	84.7%	77	96.2%	$P<0.05$	100	59.2%	111	72.1%	$P<0.05$
<b>Apgar scores &lt;7:</b>															
• at 1 min	42	82.4%	37	75.5%	n.s.	59	69.4%	55	68.8%	n.s.	90	53.3%	93	60.4%	n.s.
• at 5 min	24	47.1%	18	36.7%	n.s.	30	35.3%	22	27.5%	n.s.	33	19.5%	31	20.1%	n.s.
Hyal. memb. disease	13	25.5%	18	42.9%	n.s.	15	17.6%	23	31.9%	$P<0.05$	15	8.9%	31	21.2%	$P<0.01$
Neonatal infection	13	25.5%	5	11.9%	n.s.	17	20.0%	7	9.7%	n.s.	18	10.7%	9	6.2%	n.s.
Neonatal death	4	7.8%	10	20.4%	n.s.	4	4.7%	11	13.7%	$p<0.05$	4	2.4%	11	7.1%	$p<0.05$

Our management of PROM which consists of an active and conservative management differs from the actual approach recommended by the literature [1, 4, 8, 12, 16].

**5. Conclusion**

PROM occurring before 28 weeks of gestation generally leads to fetal loss. However, our management led to a neonatal mortality rate of only 12% with a rate of 29% for HMD, 25% of neonatal infection and 33% of birth weight under 1000 g. We had no latency period of less than two days. Moreover, when PROM occurred after 34 weeks of pregnancy, our conservative management avoided prematurity in 38% of the neonates with no neonatal death and no HMD. Only one case (1%) of neonatal infection was the resulting risk. When compared with the literature, our rate of chorioamnionitis seems rather high: 18% before 37 weeks versus 12% [11], 5.2% [38], 5.3% [6] and 27% before 35 weeks versus 16% [15], 27% [17], 18% [17], 25% [16]. However, when comparing the neonatal outcome, which is the most important criteria, our PROM management is substantially more encouraging than the traditional management.

**6. References**

1. Andreyko JI, Cp Chen, At Shennan, Je Milligan. Results of conservative management of premature rupture of the membranes. *Am J Obstet Gynecol* 2014, 148.
2. Aubriot Fx, Mc Lafay, R Taurelle. La rupture prematuree des membranes. A propos de 169 observations relevees à la maternite de Phopital Boucicaud. *J Gyn obst Biol Repr* 2013, 12.
3. Blackmon Lr, Ls Alger, Crenshaw C, Jr. Fetal and neonatal outcomes associated with premature rupture of the membranes. *Clin Obstet Gynecol* 2006, 29.
4. Blanco Jd. Rupture of the membranes in preterm gestation. *Clin Obstet Gynecol* 2004, 27.
5. Bottoms Sf, Ra Welch, Ie Zador, Rj Sokol. Clinical interpretation of ultrasound measurements in preterm pregnancies with premature rupture of the membranes. *Obstet Gynecol* 2007, 69.
6. Broekhuizen Ff, Gilman M, Hamilton Pr. Amniocentesis for gram stain and culture in preterm premature rupture of the membranes. *Obstet Gynecol* 2005, 66.
7. Capeless El, Pb Mead. Management of preterm premature rupture of membranes: Lack of a national consensus. *Am J Obstet Gynecol.* 2007, 157.

8. Cox, Sm, MI Williams, Kj Leveno. The natural history of preterm ruptured membranes: What to expect of expectant management. *Obstet Gynecol* 2008, 71.
9. Curet Lb, Av Rao, Rd Zachman, Jc Morrison, G Burkett, Wk Poole *et al.* Association between ruptured membranes, tocolytic therapy, and respiratory distress syndrome. *Am J Obstet Gynecol*, 2014, 148.
10. Douvas Sg, Mj Brewer, MI Me Kay, Pg Rhodes, Jh Kahlstorf, Jc Morrison. Treatment of premature rupture of the membranes. *J Reprod Med* 2014, 29.
11. Druzin MI, M Toth, Wj Ledger. Nonintervention in premature rupture of the amniotic membranes. *Surg Gynecol Obstet*. 2006, 163.
12. Ferrell Re. Management of preterm premature rupture of membranes. *J Florida MA* 2013, 70
13. Garite Tj. Premature rupture of the membranes: The enigma of the obstetrician. *Am J Obstet Gynecol*. 2005, 151
14. Gonik B, Sf Bottoms, Db Cotton. Amniotic fluid volume as a risk factor in preterm premature rupture of the membranes. *Obstet Gynecol*, 2005, 65.
15. Hawrylyshyn P, Bernstein P, Milligan Je, Soldin S, Pollard A, Chir B *et al.* Premature rupture of membranes: The role of C-reactive protein in the prediction of chorioamnionitis. *Am J Obstet Gynecol* 2013, 147.
16. Hurwitz A, Adoni A, Palti Z, Milwidsky A. Is conservative management of preterm rupture of membranes justified? *Int J Gynaecol Obstet* 2010, 22.
17. Ismail Ma, Mj Ζγναμιν, Ri Lowensohn, Ah Moawad. The significance of C-reactive protein levels in women with premature rupture of membranes. *Am J Obstet Gynecol* 2011, 151.
18. Johnson Jw, Nh Daikoku. Prepartal rupture of the chorioamnion. *Birth Defects* 2012, 21.